Extreme thrombocytosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors

Sorà, Federica; Autore, Francesco; Chiusolo, Patrizia; Marietti, Sara; Bayer, Jolanta; Laurenti, Luca; Giammarco, Sabrina; Ausoni, Giuseppe; Leone, Giuseppe; Sica, Simona

doi:10.3109/10428194.2014.909038

Cited by 7 publications

(11 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sorà et al2 reviewed the behavior of CML with extreme thrombocytosis at their center, and of 100 CML patients, only one patient developed thrombosis at diagnosis, while no patients reported a history of bleeding. Rice and Popat23 reported two cases of females who initially presented with only severe thrombocytosis and vascular events (stroke and myocardial infarction) and later developed typical features of CML.…”

Section: Discussionmentioning

confidence: 99%

Analysis of clinical characteristics and efficacy of chronic myeloid leukemia onset with extreme thrombocytosis in the era of tyrosine kinase inhibitors

Liu

Fan

et al. 2017

OTT

View full text Add to dashboard Cite

The aim of this study was to investigate the clinical characteristics and efficacy of chronic myeloid leukemia (CML) onset with extreme thrombocytosis. A total of 121 newly diagnosed and untreated CML patients in chronic phase with complete clinical information from the First Hospital of Jilin University, from January 2010 to December 2014 were retrospectively recruited. Based on the platelet (PLT) count, 22 patients were assigned into CML with thrombocytosis (CML-T) group (PLT >1,000×109/L) and 65 patients were classified into CML without extreme thrombocytosis (CML-N) group (PLT ≤1,000×109/L). Fifty-four point five percent of patients in the CML-T group were female, which was higher than that in the CML-N group (27.7%) (P=0.022). Except for gender, there was no significant difference for clinical information of patients between the two groups. For Sokal and Hasford scoring systems, the percentage of patients at high risk in the CML-T group were higher than those in the CML-N group, 95.5% vs 52.3% (P=0.000) and 68.2% vs 41.5% (P=0.031), respectively; however, there was no significant difference for European Treatment and Outcome Study (EUTOS) score system between the two groups (P=0.213). In terms of major molecular response (MMR) rate, the percent of patients with MMR in CML-T group was lower than that in CML-N group at 36 months after tyrosine kinase inhibitor therapy (P=0.037). Up until December 2016, the median of event-free survival was 21 months in the CML-T group, however, that was not reached in the CML-N group (P=0.027). The majority of CML patients with extreme thrombocytosis were females, and compared to patients in the CML-N group, the percentage of high risk patients based on the Sokal and Hasford scoring systems was higher in the CML-T group, and the median event-free survival of patients was shorter.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of clinical characteristics and efficacy of chronic myeloid leukemia onset with extreme thrombocytosis in the era of tyrosine kinase inhibitors

Liu

Fan

et al. 2017

OTT

View full text Add to dashboard Cite

show abstract

“…The natural history and the optimal treatment of this entity are not well characterized. We have previously reported our monocentric experience (Sorà et al , ); based on these results, we evaluated the incidence, clinical characteristics and outcome of this CML variant in a large series of patients from 16 different Italian haematological centres.…”

Section: Patient Characteristicsmentioning

confidence: 99%

Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome

et al. 2017

Self Cite

View full text Add to dashboard Cite

“…Absolute basophilia and absolute eosinophilia are the most common supplementary peripheral blood findings in the chronic phase of CML [1]. Cases such as atypical presentation of isolated thrombocytosis without leucocytosis [2][3][4] with the sole presence of p190 BCR-ABL1 fusion transcript, absolute monocytosis, and features intermediate between CML and chronic myelomonocytic leukemia (CMML) have also been described [5][6][7].…”

Section: Discussionmentioning

confidence: 99%

Eosinophilia With Hepatic Mass and Abnormal Liver Function Tests: An Unusual Presentation of Chronic Myeloid Leukemia

et al. 2020

View full text Add to dashboard Cite

Chronic myeloid leukemia (CML) is a chronic myeloproliferative neoplasm characterized by excess granulocytes at different stages of maturation and the presence of BCR-ABL1 fusion gene or Philadelphia chromosome. Absolute eosinophilia, basophilia, and monocytosis are not uncommon in CML. However, a rare entity called eosinophilic variant of CML (eoCML) can present with eosinophilia without excess neutrophils or basophils. Here, we report a rare and unusual case of eoCML presenting as a liver mass with abnormal liver function tests, which has not been reported in the literature so far.

show abstract

Extreme thrombocytosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors

Cited by 7 publications

References 14 publications

Analysis of clinical characteristics and efficacy of chronic myeloid leukemia onset with extreme thrombocytosis in the era of tyrosine kinase inhibitors

Analysis of clinical characteristics and efficacy of chronic myeloid leukemia onset with extreme thrombocytosis in the era of tyrosine kinase inhibitors

Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome

Eosinophilia With Hepatic Mass and Abnormal Liver Function Tests: An Unusual Presentation of Chronic Myeloid Leukemia

Contact Info

Product

Resources

About